Angiopoietin inhibitor, trebananib, did not extend overall survival (OS) in a Phase 3 study in ovarian cancer. In the TRINOVA-1 trial of 900 women with recurrent ovarian cancer following platinum-based chemotherapy, patients receiving trebananib plus paclitaxel had a 19.3 month overall survival versus 18.3 months OS for women receiving paclitaxel, alone.  The difference was not statistically significant. Continue reading →